Congenital left-sided cardiac lesions (LSLs) are a significant contributor to the mortality and morbidity of congenital heart disease (CHD). Structural copy number variants (CNVs) have been implicated in LSL without extra-cardiac features; however, non-penetrance and variable expressivity have created uncertainty over the use of CNV analyses in such patients. High-density SNP microarray genotyping data were used to infer large, likely-pathogenic, autosomal CNVs in a cohort of 1,139 probands with LSL and their families. CNVs were molecularly confirmed and the medical records of individual carriers reviewed. The gene content of novel CNVs was then compared with public CNV data from CHD patients. Large CNVs (>1 MB) were observed in 33 probands (∼3%). Six of these were de novo and 14 were not observed in the only available parent sample. Associated cardiac phenotypes spanned a broad spectrum without clear predilection. Candidate CNVs were largely non-recurrent, associated with heterozygous loss of copy number, and overlapped known CHD *Contributed equally to this work. †
genomic regions. Novel CNV regions were enriched for cardiac development genes, including seven that have not been previously associated with human CHD. CNV analysis can be a clinically useful and molecularly informative tool in LSLs without obvious extra-cardiac defects, and may identify a clinically relevant genomic disorder in a small but important proportion of these individuals.
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aortic stenosis, chromosome, coarctation aorta, congenital heart disease, genetic, hypoplastic left heart syndrome 1 | INTRODUCTION DNA copy number variants (CNVs) have been associated with a variety of human diseases or susceptibility to diseases (Feuk, Carson, & Scherer, 2006) . Population-based studies have demonstrated that large CNVs greater than 250 kilobases (kb) in size are significantly enriched among individuals with developmental disorders (Cooper et al., 2011) and birth defects (Southard, Edelmann, & Gelb, 2012) , and CNVs greater than 1 megabase (Mb) in size carry an even higher risk of clinical abnormalities . Therefore, large CNVs, particularly those that occur de novo, are more likely to be pathogenic and have an important clinical impact. The role of pathogenic CNVs in developmental delays/intellectual disabilities, dysmorphic features, autism spectrum disorder, and multiple congenital anomalies is now well established, with an estimated test yield of 5-15% (Ellison et al., 2012) .
CNVs are also important genetic contributors to congenital heart disease (CHD) in the presence of additional birth defects and developmental delays. Multiple studies have identified CNV susceptibility loci in CHD Goldmuntz et al., 2011; Greenway et al., 2009; Hitz et al., 2012; Lalani et al., 2013; Payne, Chang, Koenig, Zinn, & Garg, 2012; Thienpont et al., 2007; TomitaMitchell et al., 2012; Warburton et al., 2014) , but lack of controls and conflation of cardiac phenotypes in several previous studies limit their clinical applicability to LSLs. Many of the CNVs have also been observed among apparently unaffected population-based controls, implying that penetrance is incomplete, making genetic counselling of families with such CNVs more difficult. Likely pathogenic CNVs have been observed more often in individuals with CHD but without developmental delays, dysmorphic features, or other birth defects (hereafter called isolated CHDs) than in children without CHD (Kim et al., 2016) , but the utility of CNV analysis in this group of individuals has remained equivocal; in turn, this has meant that genetic testing for CNVs in isolated CHDs controversial (Connor et al., 2014) .
Grouping of CHDs together in studying CNVs also potentially dilutes important developmental and clinical categorizations. Left sided lesions (LSLs) constitute 14-20% of all CHDs, and include hypoplastic left heart syndrome (HLHS), Shone complex, mitral valve atresia, coarctation of the aorta (CoA), aortic valve stenosis (AS), and bicuspid aortic valve (BAV) (Lalani & Belmont, 2014) . These lesions have a particularly high morbidity and mortality, consuming a high proportion of resources in pediatric cardiology centers (Czosek et al., 2013) . LSLs occur in the context of chromosomal disorders, such as Turner and Jacobsen syndrome, as well as in monogenic disorders where there is often CHD concurrent with additional clinical complications (syndromic CHD), evident in Kabuki and Adams-Oliver syndromes. Isolated LSLs appear to have a more complex origin, although familial clustering of cases and an increased risk of LSL in first degree relatives strongly supports a significant genetic contribution (Kerstjens-Frederikse et al., 2011; McBride et al., 2005 McBride et al., , 2009 ). Few previous papers on the role of CNVs in this category of CHDs have been published (Table 1) . Most have not distinguished between isolated and syndromic cases (Geng et al., 2014; Glessner et al., 2014; Hitz et al., 2012; Payne et al., 2012; Warburton et al., 2014; White et al., 2014) and have typically included broad case descriptions and CNVs with variable levels of presumed pathogenicity.
The primary purpose of this study was to identify large de novo genomic events of potential clinical impact in a large cohort of individuals with LSLs. At the time of recruitment all probands had what was considered to be isolated LSL. We catalogued the clinical presentations of the probands with large events and compared the regions and genes identified with CNVs observed in a large database of controls and with previous reports. Finally, we established the rate of CNVs among individuals with isolated LSLs, demonstrating that CNVs represent a clinically important cause of these defects.
| MATERIALS AND METHODS

| Samples and subjects
Probands and their family members were enrolled through three sites: | 2177 (Hanchard et al., 2016; Lewin et al., 2004; McBride et al., 2009 ).
Patients were eligible for the study if they were willing to have DNA taken and banked, and had a characteristic LSL lesion without overt extra-cardiac involvement; that is, non-dysmorphic/non-syndromic in the opinion of the treating physician, and no overt suspicion of other birth defects at the time of enrollment. The primary inclusion criterion was a congenital LSL cardiac defect; therefore, all age-groups were eligible for enrollment, although the vast majority were recruited in infancy and early childhood (PCH median age at recruitment 9.25 years, range: birth-46 years; TCH median age 3.7 years, range: birth-45 years; NCH median age 9.1 years, range: birth-46 years; 67% We also included individuals if they had a BAV in addition to their primary malformation. Diagnoses were confirmed by echocardiography, cardiac catheterization, or direct observation at cardiac surgery. DNA from all samples was extracted, processed, and quantified using standard protocols. We did not separate our analyses on the basis of specific LSL lesions or geographical ascertainment; epidemiologically, the phenotypic and developmental overlap between LSLs justifies a combined analysis (Botto, Lin, Riehle-Colarusso, Malik, & Correa, 2007 ) and the case definition used was uniform across included sites.
Details of the LSL diagnosis demography and family structures for all recruited probands are given in (Supplementary Table S1 ).
| SNP array genotyping of LSL families
Genotyping was undertaken in two phases, each on a separate, but related microarray platform. In the first phase (hereafter referred to as the primary cohort) 797 probands and 1,047 parents and siblings were genotyped using an iScan system for HumanOmniExpress-12 v1.0
BeadChips (Illumina, CA) according to manufacturer's instructions.
These microarrays include ∼750,000 markers and are designed to 
| CNV analysis
In the family-based dataset, an annotated file of the LogR Ratio, B-allele frequency and corresponding genotype for each SNP was output and adapted for use with PennCNV (Wang et al., 2007) . All chromosome positions were translated to build hg19 using the UCSC lift-over tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver). CNV analysis was subsequently performed using GC wave adjustment and automatic quality control using a standard deviation for LogR Ratio of 0.2. Pericentromeric, telomeric and immunoglobulin regions were omitted from analysis. Similarly, we also omitted CNV calls with fewer than 50 SNPs in the intervening region, or data from the sex chromosomes. Fewer than 10% of samples failed sample QC in PennCNV. Probands with multiple CNV calls (>10 of any size) were removed from analysis as possible cell line artifacts. Where a proband had multiple CNV calls, the chromosome and genomic coordinates were used to resolve the difference between multiple unrelated CNVs and boundary effects in which one large CNV may have been called as several smaller CNVs. For trio analysis, we restricted our analysis to complete trios where all members of the trio passed sample QC as implemented above. PLINK (Purcell et al., 2007) was used to identify non-Mendelian inheritance and gender discrepancies that might suggest a sample swap or mislabeling. The updated trios were then passed to PennCNV. CNV partition v3.1.6 was used to visually validate large de novo CNVs called from PennCNV. We used parameter settings of a confidence of 50 and minimum of 5 SNPs to call any CNV. Large
CNVs were confirmed by visual inspection of the chromosome plots of BAF and LRR generated in the Chromosome Browser of GenomeStudio, and by comparing the CNV call from PennCNV in the same region. These large event CNVs were of high confidence and were easily detectable using either software. In phase 2 (proband-only dataset), CNV detection was limited to CNVpartition using the same parameters as above. In our analyses we observed a large number of uncertain duplication (gain) events between 1 and 1.5 Mb upon visual inspection and so limited our analysis to deletions (losses) larger than 1 Mb and duplications (gains) >1.5 Mb.
These large CNVs were validated using a quantitative PCR assay in the affected proband and tested in the available parents using the qBiomarker Copy Number PCR Assay system from Qiagen, following kit protocol. This included families where parental samples were available, but had not undergone genome-wide SNP genotyping.
Briefly, for each individual, reactions were assembled using a multicopy reference assay (cat. No. VPH000-0000000A) and a site-specific copy number PCR assay (see Supplemental Data). For each assay, reactions were completed in quadruplicate. Calibrator DNA was also included on each tray as a control. Each ten-microliter reaction contained 8 ng genomic DNA and the recommended volumes of qBiomarker SYBR Master Mix (cat. no. 337820) and PCR Assay, either multi-reference or site specific. Thermal cycling was completed on an Applied Biosystems 7500 FAST Real-Time PCR System using recommended conditions (FAST conditions were not used). For NCH and Utah samples, if EBV-transformed lymphoblasts were used for the microarray-based analyses, primary white blood cell DNA was used for molecular confirmation. We also confirmed large CNV calls by comparing them with calls performed on the same samples using a different pipeline (Prakash et al., 2016) as part of another study of CNVs in bicuspid aortic valve. All large CNVs reported here were also observed and reported by the BAV pipeline.
| Control datasets
Datasets from the Database of Genotypes and Phenotypes (dbGAP)
were used as comparison control datasets and consisted of two datasets-the first has been previously used in a study of thoracic aortic aneurysm (Prakash et al., 2010) ; the other was matched for the OmniExpress platform. Data were derived from Genetic Epidemiology of Refractive Error in the KORA (Kooperative Gesundheitsforschung in der Region Augsburg) Study, dbGaP accession phs000303. v1.p1 (n = 3,218); and Health and Retirement Study (HRS), phs000428.v1.p1 (n = 9,428) for a total control set of n = 15,446.
CNVs in both datasets were called using PennCNV and CNV partition. Pathway and network analysis was performed using two groups of data. The first group consisted of CNVs associated with CHDs as described by (Thorsson et al., 2015) , which was used as a reference framework. Genes within CNV intervals between 1 and 10 Mb in size and also present in at least five described cases were chosen for analysis. The second group consisted of the CNVs identified in this study which included de novo or transmitted deletion and duplication CNVs > 1Mb, with the exception of the complex chromosome 9 event which was excluded (Supplementary Table S3 3 | RESULTS
| Large genomic events in LSL
CNVs were classified as likely pathogenic if they were observed de novo in a proband from a trio, or if they were not present in our control dataset. We initially focused on de novo CNV events as those most likely to be pathogenic. We confirmed large de novo CNVs in 6 of the 379 parent-trio probands (∼1.6%) and at least 14 potential de novo events (absent in the only available parent) among the remaining 760 probands (∼1.8%) ( Table 2 ). The majority of copy number losses were heterozygous and included a number of complex rearrangements, including two unbalanced translocations. We also observed 13 large events (1-2.7 Mb) that were transmitted from apparently unaffected parents. None of these large events were noted in our control datasets.
In general, transmitted events were smaller than de novo events and were usually heterozygous copy number gains (duplication). We observed multiple instances of copy number change at five chromosomal regions-11q24.2 to 11q25; 1q21.1, 15q11.2, 16p13, and 21q21.3-with both gains and losses of chromosomal material being observed at all of these regions except 21q21.3 (two gains) ( Table 2 ).
The clinical features of probands with large events ranged from uncomplicated LSL lesions to the subsequent revelation of a syndromic diagnosis (Table 2) . Three samples had evidence for CNVs at chromosome 11q24q25 − two individuals had large deletions of the region and a third had a complex deletion-duplication-deletion variant (Figure 1 ). The 11q23q24 region is associated with Jacobsen syndrome (OMIM #147791), and although both of the neonates with the distal deletion of the region subsequently died because of their complex CHD, the genetic syndromic diagnosis was made at autopsy. Similarly, the two individuals with unbalanced translocations (LO1705; OS0010)
were not suspected to be syndromic at the time of recruitment, despite having very large events. At the other end of the spectrum, the majority of individuals with large events were non-syndromic with relatively uncomplicated and unambiguous LSLs. In between these extremes were individuals with more complex LSLs and/or neurodevelopmental co-morbidities detected over time. We found these general observations to be independent of gender and ancestry (Table 2) .
| Overlap between large genomic events in LSL and cardiac developmental loci
Most of the large genomic events we observed were singleton events; therefore, we attempted to place the observed events into a broader gene-based context. When we analyzed the genes in all identified CNV regions we found that 120 of the 818 contained genes (∼15%) were associated with the biologic process GO:0048598 "embryonic morphogenesis," and 36 (4.4%) were associated with GO:0072358 "cardiovascular development" (Supplementary Table S3 Table S2 ) corroborated these findings, demonstrating a statistically significant excess of genes and processes involved in embryonic development and cardiac development or cardiac defects in multiple groups.
Half of the large events observed in our cohort (14/33) occurred outside of previous established CHD genomic regions (Thorsson et al., 2015) (Figure 2 ). Given the enrichment for cardiac developmental genes among our CNVs, we considered whether regions outside of established regions might provide insight to new CHD genes. In order to provide a framework of reference genes that would be relevant to CHD, we first interrogated the gene content of more established CHD CNVs, proxied by recurrent events recorded by (Thorsson et al., 2015) (see Methods and Supplemental Table S3 ). In this analysis, genes and processes involved in embryonic development and cardiac development or cardiac defects were represented in multiple groups that contained other genes not relevant to heart development; therefore we generated a secondary list by merging networks with cardiovascular development. The resulting network contained genes important in heart development, including transcription factors (GATA4, TBX1, NKX2-5), cell signaling pathways (Wnt, Tgf beta), laterality, extra-cellular matrix (integrins), and a variety of mediators (Supplementary Tables S3 and S4) . We then overlaid genes contained in nonoverlapping CNV intervals from this study (Supplementary Table S3) onto this merged network (Figure 3 ). Seven genes (ATP5D, BMP7, FSTL3, MED16, PCSK4, POLR2E, and PPP1R3D) in the CNV intervals from this study intersected this network, and are involved in key developmental processes, including signaling in development and chromatin remodeling. finding consistent with a recent study of CNVs in isolated CHD (Kim et al., 2016) .
Most of the large genomic events involved copy number loss. This is consistent with the few previous assessments of CNVs in CHD, and LSLs specifically and is congruent with copy number losses being more associated with a clinical phenotype. More than half of the regions implicated in our study have been previously reported as being associated with CHD or LSLs (Thorsson et al., 2015) and, also consistent with previous reports, most events were seen once in the cohort. Recurrent events included gains and losses on 1q21.1 and 15q11.2. Haploinsufficiency at both loci has been associated with a clinical phenotype that includes CHD, although both non-penetrance and/or variable expressivity have been frequently observed (BrunettiPierri et al., 2008; Glessner et al., 2014; Rosenfeld, Coe, Eichler, Cuckle, & Shaffer, 2013) ; this is consistent with our observation of inheritance from apparently unaffected parents. Visual inspection of these CNVs in parents did not suggest mosaicism. We did not, however, systematically evaluate parents for phenotypically milder cardiac phenotypes. As such the designation of "unaffected" does not exclude variable expressivity of the observed CNVs nor does it preclude ascribing pathogenicity to these CNVs. These observations are consistent with recent studies of isolated CHD in which rare lossof-function variants in cardiac genes were also often inherited (Sifrim et al., 2016) .
We observed three overlapping large events at chromosome 16p13.11-two of which were inherited from overtly unaffected parents. Smaller CNVs in both the 16p13.11 and 15q11 regions have been noted in datasets not ascertained by cardiovascular phenotype.
16p13.11 includes the MYH11 gene (MIM #160745), which has been implicated in Familial Thoracic Aortic Aneurysms and Dissections (FTAAD) (Kuang et al., 2011) , a diagnosis typically arising at or beyond the 5th decade of life, as a well as patent ductus arteriosus (PDA)-diagnosed in the neonatal period. None of the patients with CNVs in this region had a PDA; however, all three had coarctation of the aorta, underscoring the importance of MYH11 to vascular smooth muscle.
Our results imply that MYH11 variation has highly variable and pleiotropic expressivity, contributing to both an increased susceptibility to FTAAD among adult carriers and a congenital LSL aortopathy We also observed three events at chromosome 11q24 to 11qter-two de novo deletions and one complex unbalanced translocation of uncertain inheritance. This region is at the distal end of the chromosome 11q23 region that is associated with Jacobsen syndrome (MIM # 147791), in which LSLs are well described (Grossfeld et al., 2004 (Ye et al., 2010) .
Aside from CNVs affecting known CHD-genes and loci in our cohort, a collective view of the novel regions implicated in our cohort (i.e., not overlapping previously described regions) also suggested enrichment for genes known to be involved in cardiac development or CHD. For instance, our analysis implicated seven genes, including BMP7-a member of the TGF-beta signaling network, which is known to play a substantial role in cardiac development. In murine models, Bmp7 and Bmp6 appear to interact in the formation in the endocardial cushions of the developing cardiac outflow tract (Kim, Robertson, & Solloway, 2001) , and in humans, BMP7 is implicated in congenital abnormalities of the kidney and urinary tract (CAKUT), which shares substantial overlap with cardiac developmental genetics (San Agustin et al., 2016) . The genes identified by this analysis therefore represent candidates for gene-based surveys of pathogenic variation in CHDs (Homsy et al., 2015; Zaidi et al., 2013) , and could aid in the interpretation of smaller CNVs among CHD cases, which would, in turn, further improve the clinical yield of copy number testing in CHD.
FIGURE 2 CNV loci in CHD patients. The overlap of large CNV events observed in this study (light blue circles, blue lines, dark blue shading) with large (1-10 mb) CNV regions reported in more than five CHD cases by (Thorsson et al., 2015) We chose to focus strictly on large events for both clinical and technical reasons. In general, large events typically encompass a large number of genes, and thus are likely to be clinically relevant from a diagnostic standpoint (Cooper et al., 2011; Girirajan et al., 2011) . Large pathogenic CNVs may also have implications for medical management; for example, the post-operative prognosis 
